.jpg)
.png)
I am honored and excited to serve as President of the Southeast Lipid Association (SELA). My passion for lipids heralds back to the formation of the Florida Lipid Associates in 1994, led by Paul Ziajka, MD, PhD, FNLA, and some others interested in lipid research and treatment. It has been gratifying to see the progression of that passion over the years and the formation of SELA, and then the National Lipid Association (NLA).
Article By:
Ponte Vedra, FL
Diplomate, Accreditation Council of Clinical Lipidology
Greetings, National Lipid Association members! I hope this holiday season has been a joyous one. As we look back on 2014, we can reflect on the many accomplishments the NLA has put forth. And, as we look toward the New Year, we are encouraged for what’s to come — both for the NLA as a whole and for the field of clinical lipidology.
Article By:
Professor of Medicine, Emory University
Atlanta, GA
Director, Lipid Clinic and Cardiovascular Risk Reduction Program
Diplomate, American Board of Clinical Lipidology
Does your 2015 calendar include the NLA Scientific Sessions from June 11 to 14? This annual meeting will bring more than 550 lipidologists and healthcare professionals to the Palmer House Hotel in Chicago to learn about the latest research on emerging topics in lipids and other cardiovascular risks.
The National Lipid Association (NLA) was surveyed this year by the Accreditation Council for Continuing Medical Education (ACCME) and awarded Accreditation with Commendation for the next six years as a provider of continuing medical education for physicians. The NLA’s new accreditation term expires November 30, 2020.
CHICAGO — In this video, James A. Underberg, MD, discusses recommendations from the National Lipid Association for patient-centric management of cholesterol abnormalities, and how they connect with the results of the IMPROVE-IT trial presented at the American Heart Association Scientific Sessions.
Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack
More than a decade ago, researchers from Brigham and Women’s Hospital (BWH) demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.
On Sunday, Nov. 16, at the American Heart Association (AHA) Scientific Sessions, W. Virgil Brown, MD—Editor-in-Chief of the Journal of Clinical Lipidology and Founding President of the National Lipid Association (NLA)—facilitated and participated in a debate about cholesterol targets. The session (which also featured commentary from Dr. Jennifer Robinson of Iowa City) provided an opportunity to engage in thoughtful dialogue with global cardiovascular thought leaders about cholesterol targets.
By Peter H. Jones, MD, FACP, FNLA
The National Lipid Association (NLA) is excited about the upcoming 2014 American Heart Association (AHA) Scientific Sessions (Nov. 15-19, Chicago). This is the premier meeting exploring all of the latest news and science related to heart and vascular disease, and we’ll be on-site engaging in conversations with thought leaders and researchers from around the world. You should know that this meeting attracts more than 17,000 attendees from 100 countries.
Chicago, IL (Nov. 14, 2014) — The National Lipid Association (NLA), in collaboration with Guideline Central, has created a convenient pocket guide based on its recently released Recommendations for Patient-Centered Management of Dyslipidemia.